Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96

Journal of Gene Medicine

Volumn 9, Issue 2, 2007, Pages 107-121

  Yan, Jiabin ^a,b   Liu, Xuqing ^a,d   Wang, Yao ^a,d   Jiang, Xiaomo ^a,d   Liu, Huayu ^a,e   Wang, Mingying ^c   Zhu, Xiaodong ^a   Wu, Min ^a,f,g   Tien, Po ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Beijing Tiantan Biological Products Co Ltd   (China)

^d PEKING UNIVERSITY   (China)

^e TSINGHUA UNIVERSITY   (China)

^f Institute of Mircobiology   (China)

^g UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

DNA vaccine; Fusion gene; HBV; Humoral and cellular immune responses; N terminal fragment of gp96

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 96; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A ANTIBODY; TETRAMER; VIRUS DNA;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FUSION GENE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; TH1 CELL; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; FEMALE; FLOW CYTOMETRY; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; TH1 CELLS; VACCINES, DNA;

HEPATITIS B VIRUS; MUS; MUS MUSCULUS;

EID: 33947406874     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.998     Document Type: Article

References (60)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362:2089-2094.
2. Lin OS, Kelly, EB. Correct treatment stategies for chronic hepatitis B and C. Annu Rev Med 2001: 52: 29-49.
3. Moingeon P, Almond J. de Wilde M. Therapeutic vaccines against infectious diseases. Cum Dent Microbial 2003; 6: 462-471
4. Mailliard ME, Gollan A. Emerging therapeutics for chronic hepatitis B and C. Annu Rev Med 2006; 57: 155-166.
5. Chisari W, Fumart C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
6. Gurunathan S, Klinman DM, Seder M. DNA vaccines immunology, application, and optimization. Annu Rev Immunol 2000; 18:927-974.
7. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175: 633-639.
8. Kim JJ, Ayyavoo V. Bagarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
9. Toka FN, Gierynska M, Rouse BT. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J Viral 2003; 77: 12742-12752.
10. Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune response, to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320-1329.
11. Kim SJ, Suh D, Park SE, et al. Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES. Virology 2003; 314: 84-91.
12. Lima J, Jenkins C, Guerrero A, Triozzi PL, Show DR, Strong TV. A DNA vaccine encoding generic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF). Vaccine 2005; 23: 1273-1283.
13. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998: 392: 108-411.
14. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114: 1241-1244.
15. Schneider J, Gilboa SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4: 397-402.
16. Widera G, Austin M, Rabussay D. et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000: 164: 4635-4640
17. Wang Z, Troilo PJ, Wang X, et al. Detection of integration of plasmid DNA into base, genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11: 711-721.
18. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene Fid-based nucleic and immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995; 13: 1427-1430.
19. Tuting T, Gambotto A, Robbins PD, Storkus WJ, DeLeo AB. Codelivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999; 6: 629-636.
20. Nicchitt CV. Re-evaluating the role of hear-shock protein, peptide interactions in tumour immunity. Nat Rev Immunol 2003; 3: 427-432.
21. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate add adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425.
22. Li H, Zhou M, Han J. at al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragmets. J Immunol 2005; 174: 195-204.
23. Li HT, Yan JB, Li J, et al. Enhancement of humoral immune responses on HBsAg by heat shock protein gp96 and in N-terminal fragment in mace. World J Gastroenterol 2005; 11: 2658-2863.
24. Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchita CV. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 2002; 196: 1447-1459.
25. Baker-LePain JC, Sarzotti M, Nicchita CV. Glucose regulated protein 94/ glycopromtein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. J Immunol 200; 172: 4195-4203.
26. Gidalevitz T, Biswas C. Ding H, et al. Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J Biol Chem 2004; 279: 16543-16552.
27. Suzue K, Young RA. Adjuvant free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 1996; 156 873-879.
28. Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001; 8: 376-383.
29. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gone to an HSP70 gene. Cancer Res 2000; 60: 1035-1042.
30. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Diseases of the Colon and Rectum 2002; 45: 502-507.
31. Palefsky J,M, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to heat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS (London, England) 2006; 20: 1151-1155.
32. Derkay CS, Smith RJ. McClay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol, Rhinol, Laryngol 2005; 114: 730-737.
33. Trimble C, Lin CT, Hung CF. et al. Comparison of the CDB+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21: 4036-4042.
34. Garboczi DN, Hung DT, Wiley DC, HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci USA 1992; 89: 3429-3433.
35. Qu D, Mazzarella RA, Green M. Analysis of the structure and synthesis of GRP94, an abundant stress protein of the endoplasmic reticulum. DNA Cell Biol 1994; 13: 117-124.
36. Schirmbeck R, Stober D, El-Kholy S, Riedl P, Reimann J. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, kd-, and Kb-restricted HBsAg epitopes. J Immunol 2002; 168: 6253-6262.
37. Geissler M, Schirmbeck R, Reimann J, Blum HE, Wands JR. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular ad humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice. Hepatology 1998; 28: 202-210.
38. Wildbaum, G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Immunol 2000; 165: 5860-5866.
39. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
40. Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 1994; 91: 9519-9523.
41. Biragyn A, Tani K. Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253-258.
42. Wang MH, Zheng GG, Wu KF, et al. Co-immunization with M-CSFR and mM-CSF DNA vaccines is better than M-CSFR-mM-CSF fusion DNA vaccine. Haematologica 2002; 87: 1087-1094.
43. Kwissa M, Kroger A, Hauser H, Reimann J, Schirmbeck R. Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. J Mol Med 2003; 81: 91-101
44. Sin JI, Weiner DB. Improving DNA vaccines targeting viral infection. Intervirology 2000; 43: 233-246.
45. Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model J Virol 1999; 73: 501-509.
46. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23: 130-135.
47. Asea A. Kraeft SK, Kurr-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-442.
48. Tsan MF, Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol 2004; 286: C739-744.
49. Baker-LePain JC, Reed RC, Nicchirta CV. ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. Curr Opin Immunol 2003; 15; 89-94.
50. Li-Ya A, Li HT, Zhou MH, Ha S, Tien P. Cloning, expression and purification of human heat shock protein GP96 gene in Escherichia coli. Wei Sheng Wu Xue Bao 2004; 44: 834-836.
51. More S, Breloer M, Fleischer B, von Bonin A. Activation of cynotoxic T cells in vitro by recombinant gp96 fusion proteins irrespective of the 'fused' antigenic peptide sequence. Immunol Lett 1999; 69: 275-282.
52. Rapp UK, Kaufmann SH. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 2004; 16: 597-605.
53. Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM. A fusion DNA vaccine that targets antigen presenting cells increases protection from viral challenge. Proc Natl Acad Sci U S A 2000; 97: 6676-6680.
54. Robinson CR, Sauer RT. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci U S A 1998; 95: 5929-5934.
55. Trinh R. Gurbaxani B, Morrison SL, Seyfzadeh M. Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression. Mol Immunol 2004; 40: 717-722.
56. Li Y, Subjeck, J, Yang G. Repasky E, Wang XY Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006; 24: 5360-5370.
57. Billaud JN, Petersen D. Shodel F, et al. Comparative antigenicity and immunogenicity of hepadnavirus care proteins. J Virol 2005; 79: 13641-13655.
58. McNeel DG, Schiffman K, Disis ML. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1999; 93: 2653-2659.
59. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-3903.
60. Miller LL, Korn EL, Stevens DS, et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 1999; 93: 3250-3258.